Mao, L., Li, C., Dai, J., Wei, X., Gu, J., Du, Y., Kong, Y., Sheng, X., Cui, C., Chi, Z., Lian, B., Tang, B., Yan, X., Wang, X., Li, S., Zhou, L., Li, J., Wu, X., Guo, J., Si, L. (2025). Neoadjuvant camrelizumab plus apatinib and temozolomide for resectable stage II/III acral melanoma: The CAP 03-NEO trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.9512